Abstract #0901

Testing the Efficacy of GdDO3NI: A Novel Hypoxia-Targeting T1 Contrast Agent

Shubhangi Agarwal¹, Carlos Renteria¹, Xiangxing Kong², Yanqing Tian², and Vikram Kodibagkar¹

¹School of Biological and Health Systems Engineering, Arizona State University, Tempe, AZ, United States, ²Biodesign Institute, Arizona State University, Tempe, AZ, United States

Tumor hypoxia is a severe problem in oncology, leading to enhanced metastatic potential and poor response to therapies. The advent of GdDO3NI—a hypoxia-binding contrast agent, serves to facilitate therapies by highlighting hypoxic regions on tumors. Relaxivity studies were performed and image registration were executed between modalities to validate the efficacy of this novel contrast agent to pimonidazole: the gold standard for immunohistochemical hypoxia imaging. Results showed a strong correlation in tumor boundaries and hypoxic fractions between modalities. The hypoxic regions showed lower correlation than expected however, attributed to the difference in tissue content resulting from discrepancies in slice thickness.

How to access this content:

For one year after publication, abstracts and videos are only open to registrants of this annual meeting. Registrants should use their existing login information. Non-registrant access can be purchased via the ISMRM E-Library.

After one year, current ISMRM & ISMRT members get free access to both the abstracts and videos. Non-members and non-registrants must purchase access via the ISMRM E-Library.

After two years, the meeting proceedings (abstracts) are opened to the public and require no login information. Videos remain behind password for access by members, registrants and E-Library customers.

Click here for more information on becoming a member.